Michael C. Heinrich, FACP, MD, Professor of Medicine, School of Medicine, Cell and Developmental Biology Graduate Program, School of Medicine, Cancer Biology Graduate Program, School of Medicine, Program in Molecular and Cellular Biosciences, School of Medicine from Oregon Health & Science University. In this video he speaks about the ASCO GI 2022 Planetary Series – INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib.
Brief Synopsis:
This is a randomized, open-label, multinational, multicenter trial comparing the efficacy of DCC-2618 to sunitinib in GIST patients who had progressed on or were intolerant to imatinib as their first-line anticancer treatment. DCC-2618 150 mg once day (QD) (continuous dose for 6 week cycles) or sunitinib 50 mg QD will be given to approximately 426 patients in a 1:1 ratio (6 week cycles, 4 weeks on, 2 weeks off).